Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01443390 · ClinicalTrials.gov registry record
An Ancillary Pilot Trial Using Whole Genome Sequencing In Patients With Advance Refractory Cancer
A clinical trial of Advanced Cancer, sponsored by Scottsdale Healthcare.
- Completed
- Registry status
- 11
- Enrollment target
- 1
- Study location
NCT01443390 is a study of Advanced Cancer that has completed, run by Scottsdale Healthcare. The registered enrollment target is 11 participants, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01443390, a study of Advanced Cancer, has completed, sponsored by Scottsdale Healthcare.
- COMPLETED
- Registry status
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
When a patient with advanced cancer consults with a member of the Phase I drug development team, the investigators utilize all information possible to try to select a therapy for that patient which has the best chance of working for them. This information includes: 1. Past published information 2. Clinical experience and judgement 3. Immunohistochemistry for specific targets (e.g., ER) 4. Standard sequencing (e.g., for K-Ras) and other methods now available. The investigators have a new tool which warrants early exploration for what role it might eventually play in the process of selecting the best therapy for an individual patient. The basis of the current ancillary exploratory study is to gain initial experience with the operational aspects of this whole genome sequencing in this setting.
Conditions Studied
Study Locations (1)
Arizona
- Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2011-09 |
| Est. Completion | 2013-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01443390
The ClinicalTrials.gov registry entry for NCT01443390 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (96% lower). The listed sponsor is Scottsdale Healthcare, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT01443390 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT01443390 about?
NCT01443390 is a clinical study titled "An Ancillary Pilot Trial Using Whole Genome Sequencing In Patients With Advance Refractory Cancer". When a patient with advanced cancer consults with a member of the Phase I drug development team, the investigators utilize all information possible to try to select a therapy for that patient which has the best chance of working for them. This information includes: 1. Past published information 2. ...
What is the current status of trial NCT01443390?
This trial is currently completed. The enrollment target is 11 participants. The study started on 2011-09. Estimated completion is 2013-03.
What conditions does trial NCT01443390 study?
This clinical trial studies the following conditions: Advanced Cancer.
Who is sponsoring clinical trial NCT01443390?
This trial is sponsored by Scottsdale Healthcare, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01443390 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluating Disparities in Precision Oncology
RECRUITING
-
BOLSTER: Learning New Skills to Thrive
RECRUITING · NA
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients With Advanced Cancer
RECRUITING · NA
-
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.